RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
Anita Afzali 1
Michael Chiorean 2
Garrett Lawlor 3
Mark T. Osterman 3
Arteid Memaj 3
Remo Panaccione 4
Subrata Ghosh 5
1 The Ohio State University Wexner Medical Center, Columbus, United States
2 Swedish Medical Group, Seattle, United States
3 Bristol Myers Squibb, Princeton, United States
4 Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Canada
5 College of Medicine and Health, University College Cork, Cork, Ireland
Session
Clinical trials in IBD (Posters)
Conference
UEG Week 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]